IMAC (IMAC) Competitors $1.08 -0.04 (-3.57%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends IMAC vs. BEAT, EUDA, TELA, MPLN, CNTX, ANRO, RANI, DERM, CDTX, and VXRTShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include BioTelemetry (BEAT), EUDA Health (EUDA), TELA Bio (TELA), MultiPlan (MPLN), Context Therapeutics (CNTX), Alto Neuroscience (ANRO), Rani Therapeutics (RANI), Journey Medical (DERM), Cidara Therapeutics (CDTX), and Vaxart (VXRT). These companies are all part of the "medical" sector. IMAC vs. BioTelemetry EUDA Health TELA Bio MultiPlan Context Therapeutics Alto Neuroscience Rani Therapeutics Journey Medical Cidara Therapeutics Vaxart IMAC (NASDAQ:IMAC) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends. Is IMAC or BEAT more profitable? BioTelemetry has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat BioTelemetry's return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% BioTelemetry N/A -175.50%-154.96% Which has more risk & volatility, IMAC or BEAT? IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500. Which has preferable earnings and valuation, IMAC or BEAT? IMAC has higher revenue and earnings than BioTelemetry. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M1.88-$10.54MN/AN/ABioTelemetryN/AN/A-$14.64M-$0.68-4.10 Does the MarketBeat Community prefer IMAC or BEAT? BioTelemetry received 320 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.37% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote. CompanyUnderperformOutperformIMACOutperform Votes7160.17% Underperform Votes4739.83% BioTelemetryOutperform Votes39163.37% Underperform Votes22636.63% Do analysts rate IMAC or BEAT? BioTelemetry has a consensus target price of $8.00, indicating a potential upside of 186.74%. Given BioTelemetry's stronger consensus rating and higher probable upside, analysts plainly believe BioTelemetry is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioTelemetry 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IMAC or BEAT? In the previous week, IMAC had 6 more articles in the media than BioTelemetry. MarketBeat recorded 6 mentions for IMAC and 0 mentions for BioTelemetry. IMAC's average media sentiment score of 0.29 beat BioTelemetry's score of 0.00 indicating that IMAC is being referred to more favorably in the media. Company Overall Sentiment IMAC Neutral BioTelemetry Neutral Do institutionals & insiders believe in IMAC or BEAT? 24.3% of IMAC shares are owned by institutional investors. Comparatively, 7.8% of BioTelemetry shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Comparatively, 20.9% of BioTelemetry shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryIMAC beats BioTelemetry on 8 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.60M$14.70M$5.20B$8.85BDividend YieldN/AN/A5.53%4.08%P/E RatioN/AN/A77.9314.95Price / Sales1.881.881,246.7687.31Price / CashN/AN/A40.9036.92Price / Book1.571.577.196.55Net Income-$10.54M-$10.54M$119.54M$226.22M7 Day Performance5.88%5.88%2.12%3.77%1 Month Performance-22.30%-22.30%-2.43%4.64%1 Year Performance-34.55%-34.55%34.52%29.21% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$1.08-3.6%N/A-34.5%$28.60M$15.22M0.00106BEATBioTelemetry1.8682 of 5 stars$2.83+14.1%$8.00+182.7%+105.1%$75.48MN/A0.001,700High Trading VolumeEUDAEUDA Health0.1897 of 5 stars$4.67+6.6%N/A+279.1%$115.02M$3.71M0.002TELATELA Bio3.4556 of 5 stars$2.89-0.3%$9.25+220.1%-37.9%$113.84M$58.45M-1.71120MPLNMultiPlan3.0012 of 5 stars$7.02+8.8%$25.00+256.1%N/A$113.51M$961.52M-0.072,800Positive NewsCNTXContext Therapeutics1.6642 of 5 stars$1.50-8.0%$6.25+316.7%+59.8%$112.50MN/A-1.467Gap DownANROAlto Neuroscience3.8473 of 5 stars$4.13-3.3%$20.00+384.8%N/A$111.25M$210,000.000.00N/ARANIRani Therapeutics3.2021 of 5 stars$2.03-1.0%$11.71+477.1%+3.5%$108.42M$2.72M-1.92110Analyst ForecastAnalyst RevisionDERMJourney Medical3.0378 of 5 stars$5.20-0.6%$9.38+80.3%N/A$107.80M$79.18M-5.5690Analyst RevisionCDTXCidara Therapeutics4.2087 of 5 stars$18.19+20.3%$30.50+67.7%+42.7%$106.54M$44.65M-0.7190News CoverageHigh Trading VolumeVXRTVaxart2.5799 of 5 stars$0.60-1.6%$3.00+400.6%-16.8%$106.33M$7.38M-1.46109Analyst RevisionPositive News Related Companies and Tools Related Companies BioTelemetry Competitors EUDA Health Competitors TELA Bio Competitors MultiPlan Competitors Context Therapeutics Competitors Alto Neuroscience Competitors Rani Therapeutics Competitors Journey Medical Competitors Cidara Therapeutics Competitors Vaxart Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMAC) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
